These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31562829)

  • 1. Phenotype, genotype and glycaemic variability in people with activating mutations in the ABCC8 gene: response to appropriate therapy.
    Reilly F; Sanchez-Lechuga B; Clinton S; Crowe G; Burke M; Ng N; Colclough K; Byrne MM
    Diabet Med; 2020 May; 37(5):876-884. PubMed ID: 31562829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort.
    Bacon S; Kyithar MP; Rizvi SR; Donnelly E; McCarthy A; Burke M; Colclough K; Ellard S; Byrne MM
    Diabet Med; 2016 Jul; 33(7):976-84. PubMed ID: 26479152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
    Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
    Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Genetics, Clinical Characteristics, and Treatment Outcomes of K
    Ngoc CTB; Dien TM; De Franco E; Ellard S; Houghton JAL; Lan NN; Thao BP; Khanh NN; Flanagan SE; Craig ME; Dung VC
    Front Endocrinol (Lausanne); 2021; 12():727083. PubMed ID: 34566892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterozygous ABCC8 mutations are a cause of MODY.
    Bowman P; Flanagan SE; Edghill EL; Damhuis A; Shepherd MH; Paisey R; Hattersley AT; Ellard S
    Diabetologia; 2012 Jan; 55(1):123-7. PubMed ID: 21989597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: A Novel
    Tang C; Meng L; Zhang P; Liang X; Dang C; Liang H; Wu J; Lan H; Qin Y
    Front Endocrinol (Lausanne); 2021; 12():758723. PubMed ID: 35002955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotype-phenotype correlations and response to glucose lowering therapy in subjects with HNF1β associated diabetes.
    Ng N; Mijares Zamuner M; Siddique N; Kim J; Burke M; Byrne MM
    Acta Diabetol; 2022 Jan; 59(1):83-93. PubMed ID: 34487217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
    Bowman P; Sulen Å; Barbetti F; Beltrand J; Svalastoga P; Codner E; Tessmann EH; Juliusson PB; Skrivarhaug T; Pearson ER; Flanagan SE; Babiker T; Thomas NJ; Shepherd MH; Ellard S; Klimes I; Szopa M; Polak M; Iafusco D; Hattersley AT; Njølstad PR;
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):637-646. PubMed ID: 29880308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variants of ABCC8 and phenotypic features in Chinese early onset diabetes.
    Li M; Gong S; Han X; Zhang S; Ren Q; Cai X; Luo Y; Zhou L; Zhang R; Liu W; Zhu Y; Zhou X; Sun Y; Li Y; Ma Y; Ji L
    J Diabetes; 2021 Jul; 13(7):542-553. PubMed ID: 33300273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
    Montvida O; Shaw JE; Blonde L; Paul SK
    Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
    Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis.
    Hirst JA; Farmer AJ; Dyar A; Lung TW; Stevens RJ
    Diabetologia; 2013 May; 56(5):973-84. PubMed ID: 23494446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.
    Rodbard HW; Bode BW; Harris SB; Rose L; Lehmann L; Jarlov H; Thurman J;
    Diabet Med; 2017 Feb; 34(2):189-196. PubMed ID: 27589252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.
    Østoft SH; Bagger JI; Hansen T; Pedersen O; Faber J; Holst JJ; Knop FK; Vilsbøll T
    Diabetes Care; 2014 Jul; 37(7):1797-805. PubMed ID: 24929431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
    Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment.
    Song J; Yang Y; Mauvais-Jarvis F; Wang YP; Niu T
    BMC Med Genet; 2017 Jun; 18(1):64. PubMed ID: 28587604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient neonatal diabetes due to a disease causing novel variant in the ATP-binding cassette subfamily C member 8 (
    Giannopoulou EZ; Ovcarov O; De Franco E; Kassberger F; Nusser S; Otto MC; Denzer C; Wabitsch M
    J Pediatr Endocrinol Metab; 2021 Feb; 34(2):273-276. PubMed ID: 33185579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
    Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
    J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.